By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



30 Worcester Road

Toronto  Ontario  M9W 5X2  Canada
Phone: 416-798-3001 Fax: 416-798-3007



Company News
IntelliPharmaCeutics Reports On Launch Of Additional Strengths Of Generic Focalin XR By Par Pharma 1/6/2017 8:05:01 AM
IntelliPharmaCeutics Announces Issuance Of U.S. And Canadian Patents Covering Aspects Of Its PODRAS Overdose Technology 12/21/2016 8:01:37 AM
IntelliPharmaCeutics Submits New Drug Application For Rexista® (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain 11/28/2016 7:49:58 AM
IntelliPharmaCeutics Announces Third Quarter 2016 Results 10/14/2016 10:35:21 AM
IntelliPharmaCeutics Signs An Exclusive License And Commercial Supply Agreement With Mallinckrodt (MNK) 10/12/2016 10:30:42 AM
IntelliPharmaCeutics Announces FDA Tentative Approval for Generic Seroquel XR 10/10/2016 9:00:57 AM
IntelliPharmaCeutics Responds To Recent Trading Activity 9/23/2016 8:00:25 AM
IntelliPharmaCeutics To Present At The 18th Annual Rodman & Renshaw Global Investment Conference 8/26/2016 8:03:47 AM
IntelliPharmaCeutics Announces Second Quarter 2016 Results 7/13/2016 8:15:58 AM
IntelliPharmaCeutics Reports Update On Rexista XR: FDA Grants Waiver Of NDA Filing Fee, And Topline Pharmacokinetics Results Indicate No Food Effect 7/5/2016 10:43:02 AM